Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 59.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 88,029 shares of the biotechnology company's stock after purchasing an additional 32,841 shares during the period. BNP Paribas Financial Markets owned 0.07% of Arrowhead Pharmaceuticals worth $1,655,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $38,000. Van ECK Associates Corp increased its position in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the last quarter. KBC Group NV increased its position in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $205,000. Institutional investors own 62.61% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ARWR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Citigroup lowered their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $42.13.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This represents a 1.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 275,880 shares of company stock valued at $4,034,037. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR traded down $0.26 on Friday, hitting $15.13. The stock had a trading volume of 1,230,383 shares, compared to its average volume of 1,501,861. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -2.93 and a beta of 0.89. The company's 50-day moving average is $13.32 and its two-hundred day moving average is $17.66.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same quarter last year, the company posted ($1.02) EPS. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.